Avoid common mistakes on your manuscript.
Drugs & Aging
Reassessment of the Safety of Anti-Osteoarthritis Medications
Guest Editor
Jean-Yves Reginster
Department of Public Health, Epidemiology and Health Economics, University of Liège, Belgium
WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium
Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
jyreginster@uliege.be
Ethics declarations
Disclosures
This Supplement is published on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Working Group on the safety of anti-osteoarthritis medications: Nasser Al-Daghri, Nigel Arden, Bernard Avouac, Olivier Bruyère, Roland Chapurlat, Philip Conaghan, Cyrus Cooper, Elizabeth Curtis, Elaine Dennison, Nicholas Fuggle, Gabriel Herrero-Beaumont, Germain Honvo, Margreet Kloppenburg, Stefania Maggi, Tim McAlindon, Alberto Migliore, Ouafa Mkinsi, François Rannou, Jean-Yves Reginster, René Rizzoli, Roland Roth, Thierry Thomas, Daniel Uebelhart, and Nicola Veronese.
Role of the Funding Source
The Working Group was entirely funded by the ESCEO, a Belgian not-for-profit organization. The ESCEO receives unrestricted educational grants, to support its educational and scientific activities, from Non-Governmental Organizations, not-for-profit organizations, non-commercial and corporate partners. The choice of topics, participants, content and agenda of the working groups as well as the writing, editing, submission and reviewing of the manuscript are under the sole responsibility of the ESCEO, without any influence from third parties.
Rights and permissions
About this article
Cite this article
Announcement. Drugs Aging 36 (Suppl 1), 1 (2019). https://doi.org/10.1007/s40266-019-00670-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-019-00670-z